Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
108 studies found for:    GBA
Show Display Options
Rank Status Study
21 Completed Phase I Single Dose-Escalation Safety Study of Human Glucocerebrosidase (prGCD)
Condition: Gaucher Disease
Intervention: Drug: Human Glucocerebrosidase (prGCD)
22 Completed
Has Results
A Phase III Trial to Assess the Safety and Efficacy of Plant Cell Expressed GCD in Patients With Gaucher Disease
Condition: Gaucher Disease
Intervention: Drug: Plant cell expressed recombinant glucocerebrosidase (prGCD)
23 Suspended Clinical Trial of Ambroxol in Patients With Type I Gaucher Disease
Condition: Type I Gaucher Disease
Intervention: Drug: Ambroxol
24 Completed
Has Results
A Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy in Gaucher Disease
Condition: Gaucher Disease, Type 1
Intervention: Biological: VPRIV ®,
25 Recruiting The Effect of Velaglucerase Alfa (Vpriv) on Skeletal Development in Pediatric Gaucher Disease
Conditions: Gaucher Disease Type 1;   Gaucher Disease Type 3
Intervention: Drug: Velaglucerase alfa
26 Recruiting Thrombocytopathy in Gaucher Disease Patients
Conditions: Gaucher Disease;   Thrombocytopathy
Intervention:
27 Enrolling by invitation Identification of Undiagnosed Gaucher Disease
Condition: Gaucher Disease
Intervention: Other: Enzyme analysis
28 Completed
Has Results
Auto-antibodies Prevalence and CD1 Role in Gaucher Disease
Condition: Gaucher Disease
Intervention: Genetic: genetic analyses
29 Not yet recruiting A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of GZ/SAR402671 in Parkinson's Disease Patients Carrying a Glucocerebrosidase (GBA) Gene Mutation
Condition: Parkinson's Disease
Interventions: Drug: GZ/SAR402671;   Drug: Placebo
30 Recruiting LYSO-PROVE - Determine the Prognostic Value of Lyso-Gb1 for Monitoring the Progress of Gaucher Disease
Conditions: Lysosomal Storage Diseases;   Gaucher Disease;   Sphingolipidoses
Intervention:
31 Completed
Has Results
Study of Velaglucerase Alfa Enzyme Replacement Therapy in Japanese Patients With Gaucher Disease
Condition: Gaucher Disease
Intervention: Biological: velaglucerase alfa
32 Active, not recruiting Exploration of Immunity in Gaucher Disease
Condition: Gaucher Disease
Intervention:
33 Completed Cellular and Molecular Mechanisms Governing Bone Marrow Stem Cells in Gaucher Disease
Condition: Gaucher Disease
Intervention: Other: Bone marrow and blood sampling
34 Recruiting Biomarker for Gaucher Disease
Conditions: Lysosomal Storage Diseases;   Gaucher Disease;   Sphingolipidoses
Intervention:
35 Approved for marketing Treatment Protocol of Velaglucerase Alfa for Patients With Type 1 Gaucher Disease
Condition: Gaucher Disease, Type 1
Intervention: Drug: velaglucerase alfa
36 Completed
Has Results
Study of GA-GCB Enzyme Replacement Therapy in Type 1 Gaucher Disease Patients Previously Treated With Imiglucerase
Condition: Gaucher Disease, Type 1
Intervention: Biological: GA-GCB (velaglucerase alfa)
37 Recruiting Home Therapy With VPRIV in Gaucher's Disease
Condition: Gaucher Disease
Intervention:
38 Recruiting Oxidative Stress-Related Biomarkers in Gaucher Disease: A Preliminary Study
Conditions: Gaucher Disease Type I;   Oxidative Stress
Intervention:
39 Recruiting Miglustat on Gaucher Disease Type IIIB
Condition: Gaucher Disease
Interventions: Drug: Miglustat;   Drug: ERT
40 Completed A Multicenter Study of the Efficacy of Cerezyme in Testing Skeletal Disease in Patients With Type I Gaucher Disease.
Conditions: Gaucher Disease Type I;   Cerebroside Lipidosis Syndrome;   Clucocerebrosidase Deficiency Disease;   Glucosylceramide Beta-Glucosidase Deficiency Disease;   Gaucher Disease, Non-Neuronopathic Form
Intervention: Drug: Cerezyme (imiglucerase for injection)

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.